Zhou, Yitian http://orcid.org/0000-0003-3066-5444
Dagli Hernandez, Carolina http://orcid.org/0000-0003-2109-9399
Lauschke, Volker M. http://orcid.org/0000-0002-1140-6204
Funding for this research was provided by:
FAPESP: Fundação de Amparo à Pesquisa do Estado de São Paulo
Vetenskapsrådet (2016-01153, 2016-01154, 2019-01837)
EC | Horizon 2020 Framework Programme (668353)
Article History
Received: 25 June 2020
Revised: 26 August 2020
Accepted: 2 September 2020
First Online: 25 September 2020
Ethics approval and consent to participate
: Data analysed in this work are publicly available under the Fort Lauderdale Agreement. Therefore, separated ethical approval was not required.
: Not applicable.
: All <i>DPYD</i> and <i>TPMT</i> variants with available in vivo data analysed in this study are provided in Supplementary Table S1. Sequencing data of 138,842 individuals are available atExternalRef removed.
: The authors declare no competing interests according to the ICMJE Uniform Requirements. However, V.M.L. would like to declare the following financial relationships: co-founder and shareholder of HepaPredict AB; consultancy work for Enginzyme AB. The remaining authors declare no competing interests for this work.
: This work was supported by the Swedish Research Council [grant agreement numbers: 2016-01153, 2016-01154 and 2019-01837], by the EU/EFPIA/OICR/McGill/KTH/Diamond Innovative Medicines Initiative 2 Joint Undertaking (EUbOPEN grant number 875510), by the European Union’s Horizon 2020 research and innovation program U-PGx [grant agreement number 668353] and by the Strategic Research Programmes in Diabetes (SFO Diabetes) and Stem Cells and Regenerative Medicine (SFO StratRegen). C.D.H. was supported by a fellowship from FAPESP (reference number 2019/19009-4).